For example, CpG DNA, a TLR-9 agonist, has been exploredextensively for intratumoral administration with ongoing clinicaltrials of vidutolimod demonstrating promising results in treatingadvanced melanoma cases., Another promising butless explored PRR target is retinoic acid-inducible gene I (RIG-I),a viral sensor that recognizes and binds to 5′-triphosphorylatedRNA (3pRNA) present within the cytosol. Here, RIGI is linked to melanoma.